Full Length Article

Hepatoprotective effects of glycyrrhizin and omega-3 fatty acids on Nuclear Factor-kappa B pathway in thioacetamide-induced fibrosis in rats

Nada F. Abo El-Magd a,*, Amro El-Karef b, Mamdouh M. El-Shishtawy a, Laila A. Eissa a, *

a Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt
b Department of Pathology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt

ABSTRACT

Nuclear Factor kappa B (NF-κB) is a key transcriptional regulator that plays important roles in the pathogenesis of hepatic inflammation and fibrosis in chronic liver diseases. NF-κB activation leads to production of pro-inflammatory and fibrogenic cytokines. Glycyrrhizin (GL) is reported to suppress liver fibrosis and cirrhosis. Omega-3 fatty acids (ω-3) play an anti-inflammatory role and they are reported to decrease hepatic injury in Thioacetamide (TAA) fibrotic model. We investigated the effects of GL and ω-3 on liver inflammation and fibrosis in rats and clarified the effects of these natural compounds on NF-κB level. 50 male Wistar rats randomized to 5 groups: Control group and 4 groups received TAA 200 mg/kg i.p. twice weekly for 8 weeks: TAA group, GL group (received GL 25 mg/kg daily by oral tube), ω-3 group (received ω-3 150 mg/kg daily by oral tube), (GL + ω-3) group (received similar combined doses of both natural compounds), GL and ω-3 alone or in combination protected the liver from TAA hepatotoxic effects as they significantly decreased serum AST activity and serum total bilirubin level, they also significantly increased serum albumin and total protein levels. The hepatoprotective effects of GL and ω-3 were confirmed by the histopathological analysis as they significantly reduced the necroinflammatory scores and the extent of fibrosis. GL and ω-3 significantly decreased liver malondialdehyde level (P < 0.005), liver NF-κB level (P < 0.005) and its tissue expression as detected by immunohistochemistry. In conclusion, glycyrrhizin and omega-3 fatty acids alone or in combination have potent anti-inflammatory, anti-oxidant and anti-fibrotic effects.

Copyright 2014, Mansoura University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Chronic liver diseases are an increasing cause of morbidity and mortality in more developed countries [1]. Most chronic liver diseases, including viral hepatitis (B and C), alcoholic liver disease, and biliary diseases, ultimately lead to liver fibrosis [2]. Liver fibrosis is the wound-healing response of the liver to many causes of chronic injury. Iterative liver injury causes inflammatory damage, matrix deposition, parenchymal cell death and angiogenesis leading to progressive fibrosis. The scar matrix typically accumulates very slowly but once cirrhosis is established the potential for reversing this process is decreased and complications develop [3].

Without effective treatments at an early stage, reversible liver fibrosis will lead to irreversible cirrhosis and hepatocellular carcinoma (HCC) [4]. Supplementation with antioxidants which reduce oxidative stress is an effective strategy for preventing liver fibrosis [5]. The development of targeted therapies for the management and treatment of hepatitis requires a better knowledge of the immune response mechanisms involved in the pathogenesis of liver disease [6]. Anti-fibrotic therapies are emerging that can slow, halt or reverse fibrosis progression [3].

Glycyrrhizin (GL) is the main bioactive component of licorice root extract. GL is a glycosylated saponin composed of one molecule of glycyrrhetinic acid and two molecules of glucuronide acid [7]. GL is reported to be used in chronic hepatitis resulted from different causes, such as viral infections, toxin exposure and ischemic-reperfusion injury [8]. GL has potent anti-inflammatory properties which thought to play a vital role in its hepatoprotective effects [9]. GL is reported to bind directly to high mobility group box 1 (HMGB1) so it decreases the HMGB1 concentration [10]. HMGB1 is a highly conserved protein released by injured or dying cells as a result for pathogenic products. HMGB1 plays a central role in the pathogenesis of both sterile and infectious inflammation [11]. HMGB1 may trigger an inflammatory response via activation of TLR-4 (Toll like receptor-4) pathway which activates Nuclear Factor-kappa B (NF-κB), so it enhances the production of tumor necrosis factor α (TNF-α), interleukine-1β (IL-1β) and nitric oxide [12]. Experimental strategies that selectively target HMGB1 effectively prevent activation of innate immunity and inflammation so protect different tissues against injury and damage [11].

Omega-3 fatty acids (ω-3) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are bioactive dietary compounds. Marine-derived food sources such as fatty fish, seaweed, shellfish, microalgae and krill are rich in ω-3 [13,14]. ω-3 supplements are reported to be used in hepatic injury and steatosis [15]. EPA and DHA protected against arachidonic acid produced pro-inflammatory molecules through conversion to less inflammatory mediators, so EPA and DHA have anti-inflammatory effects [16]. ω-3 are also reported to alter the production of inflammatory mediators such as chemokines, growth factors and matrix proteases [17].

Hepatitis is modulated by several mechanisms such as inflammatory signaling pathway and innate immune response [18]. Inflammation produces by an innate host defense mechanism against infections and a variety of tissue injuries. The inflammatory process passes through distinct stages, including acute, adaptive, and resolution, and moreover, inflammation may become a chronic condition as in autoimmune diseases [19]. The NF-κB system plays a vital role in regulating the innate immunity responses and cellular stress in different cell types [19,20]. NF-κB remains in the cytoplasm in unstimulated cells as a complex with inhibitory-kappaB proteins (I-κB) that prevent their translocation to the nucleus. During cell activation, I-κB is phosphorylated and dissociated, which exposes the nuclear translocation sites of NF-κB leading to translocation of NF-κB to the nucleus and DNA binding [21,22]. NF-κB composed of p65/p50 heterodimers in macrophages and binds to the promoter region of various pro-inflammatory genes leading to gene transactivation. NF-κB plays an important regulatory role in hepatic macrophage expression of pro-inflammatory mediators [22].

The aim of this study was to evaluate the potential hepatoprotective effect of GL and ω-3 alone or in combination against TAA-induced liver fibrosis in rats, and to elucidate its underlying molecular mechanism through its effect on NF-κB and oxidative stress.

2. Materials and methods

2.1. Drugs and chemicals

Thioacetamide and Glycyrrhizin (Glycyrrhizic acid ammonium salt) from licorice (Glycyrrhiza Glabra) root (Sigma–Aldrich: Sigma, St. Louis, MO, USA). Omega-3 fatty acids containing EPA and DHA in a 3:2 ratio (Lifeplan: Elizabethan Way, Lutterworth, United Kingdom).

2.2. Animals

Fifty Male Sprague–Dawley rats weighing (180–200 g) were purchased from “Egyptian Organization for Biological Products and Vaccines”, Giza, Egypt. Animals were housed and had free access to standard rat food and tap water for one week for acclimatization. The animal care and experiments described in this study were complied with “Research Ethics Committee” Faculty of Pharmacy, Mansoura University, Egypt which are in accordance with “Principles of Laboratory Animal Care” (NIH publication No. 85-23, revised 1985).

2.3. Induction of liver fibrosis

Liver fibrosis was induced according to the method of Esmat et al. [23] and Furtado et al. [24]. Forty two male Sprague-Dawley rats were intraperitoneally (i.p.) injected with freshly prepared TAA (200 mg/kg of body weight) in 0.2 ml sterile saline twice weekly (days 2 and 6) for 8 consecutive weeks.

2.4. Experimental design

Rats were distributed randomly to five groups: Control group (8 rats): injected i.p. with 0.2 ml sterile saline twice weekly (days 2 and 6) for 8 consecutive weeks, TAA group (12 rats): TAA-induced fibrotic group, GL group (10 rats): hepatic fibrosis treated with GL (25 mg/kg/day by oral tube dissolved in
distilled water) [25] for 8 weeks started with TAA, ω-3 group (10 rats): hepatic fibrosis treated with ω-3 (150 mg/kg/day by oral tube) [26,27] for 8 weeks started with TAA, GL + ω-3 group (10 rats): hepatic fibrosis treated with a combination of GL and ω-3 (received similar doses) with TAA.

2.5. Collection of blood samples and liver tissues

At the end of the experiment, rats were fasted for 12 h then 5 ml blood samples were taken from the retro-orbital puncture under light ether anesthesia. The clotted blood samples were centrifugated at 5000 rpm for 5 min for serum separation. Serum was divided into aliquots for analysis. Animals were sacrificed and the liver dissected out, rinsed in ice-cold phosphate buffer saline (PBS) pH 7.4 and blotted dry on a filter paper. A small part from right lobe of liver was cut and fixed in 10% phosphate-buffered formalin (pH 7.2) for histopathological examination. Part of the remaining liver tissues were homogenized in cold PBS then centrifuged at 5000 rpm for 15 min. The supernatant was removed for assay of malondialdehyde (MDA). While other part of the liver tissues were homogenized in cold PBS, with ultrasonic homogenizer then centrifuged at 5000 rpm for 15 min. The supernatant removed for assay of liver NF-κB. Serum samples and supernatant from liver homogenates were stored at −80 °C for biochemical analysis.

2.6. Biochemical analysis

- Serum was used for determination of ALT, AST activities, serum total bilirubin, total protein and albumin levels using commercial kits from Biodiagnostic (Cairo, Egypt).
- Liver tissue homogenate was used for assaying lipid peroxidation by measuring MDA using commercial kit from Biodiagnostic (Cairo, Egypt) and assaying Rat NF-κB using ELISA kit from Mybiosource (MBS722386) (San Diego, CA, USA).

2.7. Histopathological examination

Phosphate-buffered formalin fixed liver tissues were embedded in paraffin, then they were cut into 4 μm thick sections and they were stained with hematoxylin and eosin (H&E) and Masson’s trichrome for histopathological examination.

2.8. Assessment of necroinflammatory activity grades

Liver samples stained with (H&E) were assessed for total and individual activity parameters guided by Ishak’s activity index [28]. Classified according to the following parameters: interface hepatitis (piecemeal necrosis) (P1−P4), confluent necrosis (C0−C5), focal lobular necrosis and degeneration (FN0−FN4), and portal inflammation (P1−P4).

2.9. Quantification of fibrotic areas

Quantitative analysis of collagen fiber deposition in Masson’s trichrome stained liver tissues was performed by morphometric analysis [29]. Images were taken by a digital camera mounted on a BX51 Olympus optical microscope (Olympus Corporation, Tokyo, Japan). The NIH Image software was used for extraction and analyzing of collagenous areas stained with masson’s trichrome. The extent of fibrosis was expressed as the percentage of fibrotic area relative to the total tissue area.

2.10. Immunohistochemical detection of NF-κB

For immunohistochemistry, mouse NF-κB/65 Rabbit Polyclonal Antibody antibodies (Thermo Fisher Scientific, CA, USA) were applied to deparaffinized and rehydrated sections. After removal of the unbound primary antibodies by rinsing with PBS, slides were incubated with secondary antibody. The analysis of antibody binding was performed with a diaminobenzidine (DAB) kit, and hematoxylin was used as the counterstain. The slides were then observed by light microscopy. Expression of NF-κB was detected in the cytoplasm of liver tissue and inflammatory cells at the areas of inflammation and fibrosis (according to manufacturer instructions). Expression in different groups was compared as regards to the distribution and intensity (compared to endothelium as an internal control) and distribution of positive areas.

2.11. Statistical analysis

All the results were expressed as the mean ± Standard error (SE). One-way analysis of variance (ANOVA) followed by bonferroni test was used for analyzing statistically significant
differences between groups. P values of less than 0.05 were considered significant. The analysis was carried out using Statistical Package for the Social Sciences (SPSS) version 18. Graphs were performed with GraphPad Prism V 5.02 (GraphPad Software Inc., San Diego, CA, USA).

3. Results

3.1. Effect of GL and \( \omega-3 \) on liver function

Thioacetamide produced liver fibrosis characterized by significant increase in serum ALT and AST activities compared with control group (\( P < 0.005 \)), while treatment with GL or \( \omega-3 \) had no significant change in ALT activity, but significantly decreased AST activity compared with TAA group (\( P < 0.05 \)). Treatment with GL and \( \omega-3 \) combination significantly decreased serum ALT and AST activities compared with TAA group (\( P < 0.05, P < 0.005 \)), respectively, and significantly decreased serum ALT and AST activities compared with either GL or \( \omega-3 \) groups (\( P < 0.05 \)), as shown in (Fig. 1).

![Fig. 2](image)

**Fig. 2** — Effect of thioacetamide (TAA) (200 mg/kg twice weekly for 8 weeks), glycyrrhizin (GL) (25 mg/kg) and omega-3 fatty acids (\( \omega-3 \)) (150 mg/kg) alone or in combination on (A) liver MDA level and (B) liver NF-\( \kappa \)B level. Values: (Mean ± SE). \(^*\) \( P < 0.05 \), \(^{**}\) \( P < 0.005 \) vs. Control group. \(^{##}\) \( P < 0.005 \) vs. TAA group.

![Fig. 3](image)

**Fig. 3** — Effect of thioacetamide (TAA) (200 mg/kg twice weekly for 8 weeks), glycyrrhizin (GL) (25 mg/kg daily) and omega-3 fatty acids (\( \omega-3 \)) (150 mg/kg daily) alone or in combination on (A) liver necroinflammatory score and (B) % ratio between fibrotic area to total tissue area. Values: (Mean ± SE). \(^{**}\) \( P < 0.005 \) vs. Control group. \(^{##}\) \( P < 0.005 \), \(^{#}\) \( P < 0.05 \), \(^{##}\) \( P < 0.005 \) vs. TAA group.
Thioacetamide also produced a highly significant increase in serum total bilirubin level compared with control group ($P < 0.005$). While treatment with GL and $\omega-3$ alone or in combination produced highly significant decrease in serum total bilirubin level compared with TAA group ($P < 0.005$) and there are no significant difference between GL, $\omega-3$ and GL + $\omega-3$ groups and the control group, as shown in Table 1.

Thioacetamide affected the liver function significantly as it decreased the ability of liver to synthesize the albumin and other proteins as the serum levels of albumin and total protein decreased significantly in TAA group compared with control group ($P < 0.005$). While treatment with GL and $\omega-3$ alone or in combination protected the liver as the serum levels of albumin and total protein increased significantly compared with TAA group ($P < 0.005$, $P < 0.05$), respectively and there are no

![Fig. 4](image-url)

Fig. 4 – The left vertical panel showed marked necroinflammation in the TAA group that became reduced after combined treatment with (GL + $\omega-3$) more than single treatment (arrows around bridging necrosis). The middle panel showed increased collagen deposition in TAA group with its reduction after combined treatment (GL + $\omega-3$) more than single treatment (arrows around fibrous bridges). The right panel showed increased NF-$\kappa$B expression colocalized at the same areas of necroinflammation and bridging fibrosis in TAA group with much reduced expression with combined treatment (GL + $\omega-3$) than single treatment. Thioacetamide (TAA), Glycyrrhizin (GL), Omega-3 fatty acids ($\omega-3$) and (GL + $\omega-3$) groups (magnification $\times 100$).
significant difference between GL, ω-3 and GL + ω-3 groups and the control group, as shown in Table 1.

3.2. Effect of GL and ω-3 on hepatic lipid peroxidation

Thioacetamide caused a significant increase in hepatic MDA content in comparison to control group (P < 0.005), while treatment with GL and ω-3 alone or in combination significantly decreased the elevated MDA levels compared with TAA group (P < 0.005), as shown in (Fig. 2A).

3.3. Effect of GL and ω-3 on hepatic NF-κB concentration

Thioacetamide caused significant increase in the hepatic concentration of NF-κB compared with control group (P < 0.005), while treatment with GL and ω-3 alone or in combination highly significantly decreased NF-κB level compared with TAA group (P < 0.005) and there are no significant difference between GL, ω-3 and GL + ω-3 groups and the control group, as shown in (Fig. 2B).

3.4. Effect of GL and ω-3 on hepatic necroinflammatory activity

Examination of TAA group showed moderate to severe necroinflammatory activity with average scores of (14.5) with marked piecemeal necrosis, zone 3 necrosis and multiple portal central bridging necrosis, frequent apoptosis and focal inflammation with moderate and marked portal inflammation. Treatment with GL and ω-3 alone or in combination

| Table 2 – Correlational analysis of the studied parameters. |
|----------------------------------------------------------|
| **AST activity (r)** | **Total bilirubin level** | **Albumin level** | **Total protein level** | **Liver NF-κB level** |
| AST activity (r) | 1 | 0.581* | −0.731* | −0.591* | 0.626* |
| Total bilirubin level (r) | 0.581* | 1 | −0.701* | −0.669* | 0.875* |
| Albumin level (r) | −0.731* | −0.701* | 1 | 0.594* | −0.685* |
| Total protein level (r) | −0.591* | −0.669* | 0.594* | 1 | −0.519* |
| Liver NF-κB level (r) | 0.626* | 0.875* | −0.685* | −0.519* | 1 |

* Correlation is significant at P < 0.001 level.

Fig. 5 – Positive correlation between liver NF-κB level and (A) Liver MDA level (r = 0.883), (B) Liver necroinflammatory score (r = 0.787), (C) Liver % ratio between fibrotic area to total tissue area (r = 0.758) and (D) Serum AST activity (r = 0.626).
significantly protected the liver from hepatotoxic effects of TAA reflected by reduction of necroinflammation to (10.3) (p < 0.05), (10.5) (p < 0.05) and (9) (p < 0.005), respectively and there are no significant difference between GL, ω-3 and GL+ω-3 groups and the control group, as shown in (Fig. 3A and Fig. 4, left vertical panel).

3.5. Effect of GL and ω-3 on hepatic fibrosis

Thioacetamide increased amount of collagen deposition in liver tissue stained with Masson’s trichrome significantly, while treatment with GL and ω-3 alone or in combination significantly protected the liver from this increase (P < 0.005) and there are no significant difference between GL, ω-3 and GL+ω-3 groups and the control group. So GL and ω-3 alone or in combination decreased the fibrotic areas and collagen content significantly (Fig. 3B and Fig. 4, middle vertical panel).

3.6. Expression of NF-κB

Expression of NF-κB was increased in hepatic tissues of rats injected with TAA that colocalized at the same areas of increased necroinflammation and fibrosis, while expression of NF-κB was reduced in hepatic tissues treated with GL and ω-3 alone or in combination compared with TAA group (Fig. 4, right vertical panel).

3.7. The correlation analysis of studied parameters

The data in Table 2 and Figs. 5 and 6 show the correlation analysis of all studied parameters. Liver NF-κB level positively correlated with liver MDA level (0.883, P < 0.001), liver necroinflammatory score (0.787, P < 0.001) and % ratio between fibrotic area to total tissue area (0.0758, P < 0.001), as shown in (Fig. 5). Also liver NF-κB level positively correlated with serum AST activity (0.626, P < 0.001) and serum total bilirubin level (0.875, P < 0.001). NF-κB level negatively correlated with serum albumin level (−0.685, P < 0.001) and serum total protein level (−0.519, P < 0.001), as shown in Table 2. Serum ALT activity had non-significant positive correlation with liver NF-κB level (0.243), liver necroinflammatory score (0.228) and liver % ratio between fibrotic area to total tissue area (0.275) as shown in (Fig. 6).

4. Discussion

Liver fibrosis is considered as the main complication of chronic liver diseases and a range of chronic inflammatory diseases [2]. Chronic inflammation is followed by accumulation of collagen which resulted from a cascade of events that involves cytokines produced by both liver resident cells and circulating immune cells. These inflammatory stimuli cause activation of quiescent hepatic stellate cells (HSCs) to myofibroblast like cells to produce collagen [30,31]. When hepatic fibrosis occurs, collagen (mainly types 1 and 3) proliferation accounts for 50% of the total protein in fibrotic liver [32]. With ongoing injury, fibrosis develops to bridging fibrosis with nodule formation which ends with cirrhosis and HCC. So, initial prevention of liver fibrosis is a critical strategy for curing chronic liver diseases [31].

In our study, TAA intoxication caused an intense oxidative stress as evident by the dramatic increase in the hepatic MDA level. MDA is a toxic product of peroxidation of biological membrane polyunsaturated fatty acids. Therefore the measurement of MDA is used as an indicator of oxidative stress [33]. TAA is a potent hepatotoxin, so it is used in producing hepatic injury showed lesions similar to those seen in most cases of human liver disease. TAA causes cytotoxic injury through a two-step bioactivation mediated by the microsomal cytochrome P450 isozyme E1 and/or flavin-containing monooxygenase systems. TAA converts to TAA-sulfoxide and further to a reactive metabolite, TAA-S, S-dioxide, which responsible for lipid peroxidation at the plasma membrane level [34].

Glycyrrhizin and ω-3 alone or in combination protected the liver from the oxidative stress caused by TAA as they decreased significantly the elevated liver MDA. GL and ω-3 act as scavengers of free radicals, so they decrease the oxidative stress. A decrease of lipid peroxidation mediated oxidative stress may be a potential and effective strategy for the prevention and treatment of hepatic failure [35].
Thioacetamide-induced hepatotoxic effects characterized by piecemeal necrosis, confluent necrosis, focal lytic necrosis, apoptosis, focal inflammation and portal inflammation at the tissue levels which reflected in our study by significant elevation of serum liver enzymes and bilirubin as well as increased collagen deposition and fibrotic areas significantly. GL and ω-3 alone or in combination protected liver from this inflammation at tissue level which is reflected by significant increased serum AST activity and serum bilirubin level, and decreased collagen and fibrotic areas. These are evidence for the hepatoprotective effect of GL and ω-3 alone or in combination.

Glycyrrhizin and ω-3 groups showed no significant change in ALT activities compared with TAA group. Also, there is no significant correlation between ALT activity and both liver fibrosis and liver necroinflammatory score. These may be explained as enzyme activity does not reflect the severity of fibrosis and there is no significant correlation between serum ALT activity and histological activity [36]. In accordance to these results, our observations indicated that: a decreased ALT activity in TAA group may be a result of massive necrosis and late stage of fibrosis, while decreased ALT activity in GL and ω-3 groups may be due to recovery, as decreasing ALT activity in hepatic injury occur both with recovery and with massive necrosis [36,37].

We found that TAA caused a significant increase in liver NF-κB concentration. GL, ω-3 and their combination prevented the increase in liver NF-κB concentration. So GL, ω-3 and their combination have a hepatoprotective effect through blocking NF-κB pathway, since NF-κB plays a regulatory role in liver

---

Fig. 7 — The proposed hepatoprotective mechanism of glycyrrhizin and omega-3 fatty acids in thioacetamide-induced fibrosis in rats.
fibrosis and inflammation. NF-κB modulates hepatic fibrogenesis predominantly in three different cellular compartments by: (A) Regulating hepatocyte injury, the primary trigger of fibrogenic responses in the liver; (B) Regulating inflammatory signals elicited in macrophages and other inflammatory cells in the liver and (C) Regulating fibrogenic responses in HSCs [38].

Our results indicated positive correlations between liver NF-κB level and both liver necroinflammatory score and liver collagen deposition. So we suggested that NF-κB has a critical role in the pathogenesis of fibrosis and necroinflammation development in liver. NF-κB increased significantly in TAA group, while the treatment with GL, ω-3 or their combination prevented the increase in NF-κB, so they prevented the development of liver fibrosis and necroinflammation. We also found a positive correlation between liver NF-κB level and lipid peroxidation, so oxidative stress has a positive effective role in liver inflammation and fibrosis in TAA group. The anti-oxidant properties of GL and ω-3 have also an effective role as anti-inflammatory and anti-fibrotic.

Glycyrrhizin has a variety of pharmacologic effects such as anti-inflammatory, antiviral, antioxidant, immunomodulatory, hepatoprotective and cardioprotective activities [39]. We found that GL and ω-3 have dramatic effects on NF-κB and MDA, as they significantly decreased when compared with TAA group. These results may confirm the anti-inflammatory, anti-fibrotic and anti-oxidant effects of either GL or ω-3. Studies supposed that GL binded to HMGB1 directly to suppress HMGB1-induced injury, inhibit TLR-4 pathway, lower NF-κB concentration and inhibit the production of inflammatory cytokines [40–42]. ω-3 reduced the inflammation by lowering NF-κB concentration. Lowering NF-κB inhibited the production of inflammatory cytokines including TNF-α and IL-1β, reduced arachidonic acid–derived eicosanoids and protected against oxidative stress [43,44]. Studies found that ω-3 decrease the production of inflammatory proteins which may be mediated by altered activation of key transcription factors in regulating inflammatory gene expression, such as NF-κB and peroxisome proliferator activated receptors (PPAR-γ, δ) [45]. Both NF-κB and PPAR-γ may be regulated by ω-3 [17,43].

Fig. 7 indicates our proposed hepatoprotective mechanisms of GL and ω-3 in TAA-induced fibrosis in rats. GL protected the liver from TAA-toxic effects through decreasing liver NF-κB level which indicated the blocking HMGB1. It also decreased the lipid peroxidation. Also, ω-3 decreased NF-κB level and the lipid peroxidation so they protected the liver from TAA-toxic effects.

We found that GL, ω-3 and their combination have high protection potency against liver fibrosis as they decrease the collagen deposition, fibrotic areas, oxidative stress, NF-κB level and tissue expression, pro-inflammatory cytokines and fibrogenic cytokines. We also found that the protection potency of either GL or ω-3 alone is the same as their combination against liver fibrosis.

5. Conclusions

The results of the current study supported the potential role of NF-κB in liver fibrosis and demonstrated that the hepatoprotective effect of glycyrrhizin and omega-3 fatty acids alone or in combination against liver fibrosis as they decreased both the fibrotic areas and the necroinflammatory scores. The mechanism behind hepatoprotective effects of glycyrrhizin and omega-3 fatty acids included suppression of oxidative stress and Inhibition of NF-κB. So the hepatoprotective effects of glycyrrhizin, omega-3 fatty acids and their combination against TAA-induced fibrosis appear to be mediated via its antioxidant, anti-inflammatory and anti-fibrotic properties. We advise to fulfill some clinical studies on these natural compounds as nutrient to protect against liver fibrosis.

REFERENCES

[1] Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study. Lancet 2010;2012(380):2095–128.
[2] Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011;6:425–56.
[3] Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014;14:181–94.
[4] Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209–18.
[5] Gebhardt R. Oxidative stress, plant-derived antioxidants and liver fibrosis. Planta Med 2002;68:289–96.
[6] Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol 2008;22:991–1008.
[7] Tolstikov GA, Baltina IA, Shul’ts EE, Pokrovskii AG. Glycyrrhizic acid. Bioorg Khim 1997;23:691–709.
[8] Del Prete A, Scalera A, Iadevaia MD, Miranda A, Zulli C, Gaeta L, et al. Herbal products: benefits, limits, and applications in chronic liver disease. Evid Based Compl Altern Med 2012;2012:837939.
[9] Kimura M, Moro T, Motegi H, Maruyama H, Sekine M, Okamoto H, et al. In vivo glycyrrhizin accelerates liver regeneration and rapidly lowers serum transaminase activities in 70% partially hepatectomized rats. Eur J Pharmacol 2008;579:357–64.
[10] Sita G, Iamacone M, Muller S, Bianchi ME, Guidotti LG. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HIV transgenic mice. J Leukoc Biol 2007;81:100–7.
[11] Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011;29:139–62.
[12] Bianchi ME. HMGB1 loves company. J Leukoc Biol 2009;86:573–6.
[13] Kromhout D, de Goede J. Update on cardiometabolic health effects of omega-3 fatty acids. Curr Opin Lipidol 2014;25:85–90.
[14] Lorente-Cebrian S, Costa AG, Navas-Carretero S, Zabala M, Martinez JA, Moreno-Aliaea MJ. Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence. J Physiol Biochem 2013;69:633–51.
[15] Marsman HA, de Graaf W, Heger M, van Golen RF, Ten Kate FJ, Bennink R, et al. Hepatic regeneration and functional recovery following partial liver resection in an experimental model of hepatic steatosis treated with omega-3 fatty acids. Br J Surg 2013;100:674–83.
[16] Larsen R, Eilertsø KE, Elvøe EO. Health benefits of marine foods and ingredients. Biotechnol Adv 2011;29:508–18.
Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients 2010;2:355–74.

Ajuebor MN, Carey JA, Swain MG. CCR5 in T cell-mediated liver diseases: what’s going on? J Immunol 2006;177:2039–45.

Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol 2009;27:693–733.

Ghosh S. Regulation of inducible gene expression by the transcription factor NF-κB. Immunol Res 1999;19:183–9.

Baldwin AS. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649–81.

Mandrekar P, Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol 2009;5:1258–66.

Esmat AY, Said MM, Soliman AA, El-Masry KS, Badiea EA. Bioactive compounds, antioxidant potential, and hepatoprotective activity of sea cucumber (Holothuriaatra) against thioacetamide intoxication in rats. Nutrition 2013;29:258–67.

Furtado KS, Prado MG, Aguiar E, Silva MA, Dias MC, Rivelli DP, et al. Coffee and caffeine protect against liver injury induced by thioacetamide in male wistar rats. Basic Clin Pharmacol Toxicol 2012;111:339–47.

Zhao J, Wan X, Luo M, Chen T, He P. Antifibrotic effects of glycyrrhizin and matrine in vitro and in vivo. Biomed Prev Nutr 2012;2:132–7.

Shaaban AA, Shaker ME, Zalata KR, El-kashef HA, Ibrahim TM. Modulation of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis by olmesartan and omega-3. Chem Biol Interact 2014;207:81.

Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090–8.

Ishak KG, Bapitesta A, Bianchi L, Callea F, DeGroot J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9.

James J, Bosch KS, Aronson DC, Houtkooper JM. Sirius red histophotometry and spectrophotometry of sections in the assessment of the collagen content of liver tissue and its application in growing rat liver. Liver 1990;10:1–5.

Schuppan D, Gorrell MD, Klein T, Mark M, Afshal NH. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int 2010;30:795–808.

PG Traber, Chou H, Zomer E, Hong F, Klyosov A, Fiel MI, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS One 2013;8:e75361.

Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001;21:373–84.

Vaca CE, Wilhelm J, Harms-Ringdahl M. Interaction of lipid peroxidation product with DNA, a review. Mutat Res Genet Toxicol 1988;195:137–49.

Hessien M, El-Sharkawi I, El-Barbary A, Beltagy DM. Regression of thioacetamide, alcohol and schistosomiasis induced liver fibrosis in mice by silymarin. Turk J Biochem 2008;33:131–7.

Tsuchiya D, Hong S, Matsumori Y, Shiina H, Kayama T, Swanson RA, et al. Overexpression of rat heat shock protein 70 is associated with reduction of early mitochondrial cytochrome c release and subsequent DNA fragmentation after permanent focal ischemia. J Cereb Blood Flow Metab 2003;23:718–27.

Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995;90:1250–7.

Tygstrup N, Ranek L. Assessment of prognosis in fulminant hepatic failure. Semin Liver Dis 1986;6:129–37.

Luedde T, Schwabe RF. NF-κB in the liver linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011;8:108–18.

Asl MN, Hosseinizadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res 2008;22:709–24.

Gwak GY, Moon TG, Lee DH, Yoo BC. Glycyrrhizin attenuates HMGB1 induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway. World J Gastroenterol 2012;18:679–84.

Youn JH, Oh YJ, Kim ES, Choi JE, Shin JS. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 2008;180:5067–74.

Mollica I, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, et al. Glycyrrhizin binds to high mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007;14:431–41.

Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr 2013;33:231–48.

Xiao C, Ghosh S. NF-kappaB, an evolutionarily conserved mediator of immune and inflammatory responses. Adv Exp Med Biol 2005;560:41–5.